While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here is one cash-producing company that excels at turning cash into shareholder value and two that may face some trouble.
Two Stocks to Sell:
G-III (GIII)
Trailing 12-Month Free Cash Flow Margin: 5.8%
Founded as a small leather goods business, G-III (NASDAQ: GIII) is a fashion and apparel conglomerate with a diverse portfolio of brands.
Why Is GIII Risky?
- 6% annual revenue growth over the last five years was slower than its consumer discretionary peers
- Annual earnings per share growth of 3.5% underperformed its revenue over the last five years, showing its incremental sales were less profitable
- Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 8.2% for the last two years
At $34.63 per share, G-III trades at 14.6x forward P/E. Check out our free in-depth research report to learn more about why GIII doesn’t pass our bar.
Inspired (INSE)
Trailing 12-Month Free Cash Flow Margin: 3.9%
Specializing in digital casino gaming, Inspired (NASDAQ: INSE) is a provider of gaming hardware, virtual sports platforms, and server-based gaming systems.
Why Do We Avoid INSE?
- Muted 12.1% annual revenue growth over the last five years shows its demand lagged behind its consumer discretionary peers
- Operating margin of 12.2% falls short of the industry average, and the smaller profit dollars make it harder to react to unexpected market developments
- Low free cash flow margin of 5.1% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
Inspired is trading at $8.11 per share, or 28.2x forward P/E. Read our free research report to see why you should think twice about including INSE in your portfolio.
One Stock to Buy:
DexCom (DXCM)
Trailing 12-Month Free Cash Flow Margin: 29.7%
Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ: DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks.
Why Should You Buy DXCM?
- Core business is healthy and doesn’t need acquisitions to boost sales as its organic revenue growth averaged 12.5% over the past two years
- Free cash flow margin expanded by 26 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
- Improving returns on capital reflect management’s ability to monetize investments
DexCom’s stock price of $74.56 implies a valuation ratio of 28.2x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
